DCPH - Deciphera Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Deciphera Pharmaceuticals, Inc.

500 Totten Pond Road
6th Floor
Waltham, MA 02451
United States

Full Time Employees112

Key Executives

NameTitlePayExercisedYear Born
Mr. Steven L. HoerterPres, CEO & Director42.19kN/A1971
Mr. Thomas Patrick Kelly J.D.Exec. VP, CFO & Treasurer556kN/A1971
Mr. Daniel C. MartinChief Commercial Officer807.17kN/A1975
Dr. Daniel L. FlynnExec. VP, Chief Scientific Officer & FounderN/AN/A1955
Dr. Stephen B. Ruddy Ph.D.Chief Technical OfficerN/AN/A1964
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. It is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for treatment of solid tumors and hematologic malignancies; and Rebastinib, which is in Phase 1b/II trial to treat solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.

Corporate Governance

Deciphera Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 8. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.